SCHEMBL3003585

SCHEMBL3003585

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)c(F)c4)cs3)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.58
RECQL P46063 2/20 0.58
USP2 O75604 2/20 0.58
HSD17B10 Q99714 1/20 0.58
KMT2A Q03164 4/20 0.51
POLB P06746 1/20 0.49
ALDH1A1 P00352 6/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 5/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 3/20 0.48
HTT P42858 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653491 0.94 MAPT (0.54) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3011924 0.93 MAPT (0.58) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3021751 0.93 MAPT (0.58) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3006380 0.93 MAPT (0.60) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3013758 0.92 MAPT (0.56) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3007502 0.92 MAPT (0.56) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3011600 0.90 MAPT (0.51) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3000043 0.89 MAPT (0.54) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3003931 0.89 MAPT (0.60) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3012041 0.89 POLB (0.59) MAPTRECQLUSP2HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.